Evidence map›Paper›PMID 36842100›Full record

ArticleThe Prostate2023

Prevalence of genotoxic bacteria in men undergoing biopsy for prostate cancer.

John Lee, Brian L Wickes, Jianmin Fu, Nohelli E Brockman, Harshit Garg, Christian Jobin, Teresa Johson-Pais, Robin Leach, Zhao Lai, Michael A Liss

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Prostate, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Prostate and urinary microbiomes in prostate cancer development: focus onFrontiers in cellular and infection microbiology · 2025
    Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

John LeeDepartment of Urology, University of Texas Health San Antonio, San Antonio, Texas, USA.ORCID 0000-0003-3699-5161
Brian L WickesDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health San Antonio, San Antonio, Texas, USA.
Jianmin FuDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health San Antonio, San Antonio, Texas, USA.
Nohelli E BrockmanDepartment of Microbiology, Immunology, and Molecular Genetics, University of Texas Health San Antonio, San Antonio, Texas, USA.
Harshit GargDepartment of Urology, University of Texas Health San Antonio, San Antonio, Texas, USA.
Christian JobinDivision of Gastroenterology, Hepatology, and Nutrition, University of Florida College of Medicine, Gainesville, Florida, USA.
Teresa Johson-PaisDepartment of Urology, University of Texas Health San Antonio, San Antonio, Texas, USA.
Robin LeachDepartment of Cell and Systems Biology, University of Texas Health San Antonio, San Antonio, Texas, USA.
Zhao LaiDepartment of Molecular Medicine, University of Texas Health San Antonio, San Antonio, Texas, USA.
Michael A LissDepartment of Urology, University of Texas Health San Antonio, San Antonio, Texas, USA.ORCID 0000-0001-6978-1026
The University of Texas Health Science Center at San Antonio · USUniversity of Florida · US

Funding

Advancing Cancer Research Through Next Generation Sequencing at Mays Cancer Center of UT Health San AntonioR50CA265339 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Zhao Lai · 2022 to 2026
$957k
NCI NIH HHS R50 CA265339
6 · The paper itself

Abstract

backgroundNew evidence suggests that bacteria-produced DNA toxins may have a role in the development or progression of prostate cancer. To determine the prevalence of these genes in a noninfection (i.e., colonized) state, we screened urine specimens in men before undergoing a biopsy for prostate cancer detection.

methodsWe developed a multiplex polymerase chain reaction using three of the most described bacterial genotoxin gene primers: Colibactin (polyketone synthase [pks] gene island: clbN and clbB), cytotoxic necrotizing factor (cnf1) toxin, and cytolethal distending toxin B (cdtB) represented gene islands. After calibration on Escherichia coli samples of known genotypes, we used a training and validation cohort. We performed multiplex testing on a training cohort of previously collected urine from 45 men undergoing prostate biopsy. For the validation cohort, we utilized baseline urine samples from a previous randomized clinical trial (n = 263) with known prostate cancer outcomes.

resultsThe prevalence of four common bacterial genotoxin genes detected in the urine before prostate biopsy for prostate cancer is 8% (25/311). The prevalence of pks island (clbN and clbB), cnf1, and cdt toxin genes are 6.1%, 2.4%, and 1.7%, respectively. We found no association between urinary genotoxins and prostate cancer (p = 0.83). We did identify a higher proportion of low-grade cancer (92% vs. 44%) in those men positive for urinary genotoxin and higher-grade cancer in those genotoxin negative (8% vs. 56%, p = 0.001).

conclusionsThe prevalence of urinary genotoxins is low and does not correspond to a prostate cancer diagnosis. The urine was taken at one point in time and does not rule out the possibility of previous exposure.

Indexed as

Escherichia coliProstatic NeoplasmsBiopsyDNA DamageHumansMaleMutagensPrevalenceMutagensE. coligenotoxinprostate cancerurinary microbiome

Identifiers

PMID36842100
PMCPMC10364089
OpenAlexW4322109423

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.